We’re pleased to announce we have entered into an exclusive license agreement with MSD, a global leader in cardiovascular care, for HRS-5346, Hengrui Pharma’s investigational small oral molecule Lipoprotein(a), or Lp(a), inhibitor, currently being evaluated in a Phase 2 clinical trial in China. Elevated Lp(a) is a genetically determined condition and an independent risk factor for cardiovascular disease that affects approximately 1.4 billion people worldwide. Under the agreement, Hengrui Pharma has granted MSD exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region. Hengrui Pharma will receive an upfront payment of $200 million and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $1.77 billion, as well as royalties on net sales of HRS-5346, if approved. The transaction is expected to close in the second quarter of 2025. Read the full press release:
关于我们
恒瑞医药创立于1970年，是一家专注研发、生产及推广高品质药物的创新型国际化制药企业，聚焦抗肿瘤、代谢性疾病、自身免疫疾病、呼吸系统疾病、神经系统疾病等领域进行新药研发，是国内最具创新能力的制药龙头企业之一。 五十余年来，恒瑞医药始终坚持为患者服务的初心，努力守护患者健康生活和生命质量，攻坚克难推进医药产业高质量发展。在美国制药经理人杂志公布的全球制药企业TOP50榜单中，恒瑞医药已连续5年上榜；国际知名咨询机构Citeline发布的全球TOP25管线规模制药公司榜单，恒瑞医药连续3年上榜，2024年排名跃升至第8位，再创中国药企新高；胡润研究院发布的《2023胡润世界500强》，恒瑞医药排名第366位；中国医药工业信息中心历年发布的“中国医药研发产品线最佳工业企业”，恒瑞医药已11次登顶榜首。 恒瑞医药始终把科技创新作为第一发展战略，持续加大创新力度，累计研发投入近400亿元，位居全国医药行业前列。公司在连云港、上海、美国和欧洲等地设立14个研发中心，全球研发团队达5000余人。研发投入催生丰硕创新成果，瑞维鲁胺、卡瑞利珠单抗等14款自研1类创新药、4款自研2类新药和2款引进创新药在国内上市，另有90多个自主创新产品正在临床开发，近300项临床试验在国内外开展，形成了上市一批、临床一批、开发一批的良性循环。 恒心致远，瑞颐人生。恒瑞医药将始终坚持“科技为本，为人类创造健康生活”的使命，以“专注创新，打造跨国制药集团”为愿景，不断强化技术创新主体地位，力争研制出更多的新药、好药，服务“健康中国”，惠及全球患者。 欲了解更多信息，请访问www.hengrui.com并在LinkedIn上关注我们。
- 所属行业
- 制药业
- 规模
- 超过 10,001 人
- 总部
- Lianyungang， Jiangsu Province
- 类型
- 上市公司
- 创立
- 1970
- 领域
- Oncology、Immunology、Metabolic、Pain management和Contrast agents
地点
-
主要
获取路线
No.7 Kunlunshan Road, Lianyungang Eco & Tech Development Zone
CN， Jiangsu Province，Lianyungang，222047
恒瑞医药员工
动态
-
We are excited to announce an exclusive license agreement with IDEAYA Biosciences for the development, production and commercialization of SHR-4849, a novel DLL3 targeting antibody drug conjugate (ADC). This collaboration marks another milestone in delivering innovative medicines in areas where there is significant unmet patient need, including small cell lung cancer and neuroendocrine tumors. Under the agreement terms, Hengrui Pharma will receive upfront and milestone payments totaling over $1 billion, including a $75 million upfront payment, up to $200 million in development and regulatory milestone payments, plus commercial success-based milestones. Hengrui is also eligible to receive mid-single to low-double digit royalties on net sales outside of Greater China. As of today, Hengrui has out-licensed 12 innovative drugs to the global market and will continue to collaborate with global partners to serve a healthy China and benefit patients around the world.
-
Today, June 1 at #ASCO2024, landmark median overall survival data will be presented from the global, Phase 3 clinical study of Hengrui Pharma’s camrelizumab in combination with rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma (uHCC) (abstract #4110). This combination is the only uHCC therapy to increase median overall survival to approximately 2 years with greater than 1 in 3 patients alive at 3 years. Additionally, Hengrui Pharma’s presentations and online publications will include data from 78 of our clinical studies that cover more than 10 tumor treatment areas, showcasing our extensive portfolio and pipeline as we continue to advance therapeutic options for patients with difficult-to-treat cancers around the world.
-
We are pleased to announce that we have licensed global rights (excluding Greater China) for the development, production and commercialization of 3 of our proprietary, innovative GLP-1 drugs to a new company established and funded by a $400 million investment from Bain Capital, Atlas Venture, RTW Capital, and Lyra Capital. This collaboration marks an additional milestone in Hengrui Pharma’s continued globalization and serves as recognition of the quality of our innovation, particularly in metabolic diseases such as obesity and diabetes, where there is significant patient need. Under the agreement terms, Hengrui Pharma will receive an upfront payment of $100 million and $10 million for tech transfer, with potential for clinical development and regulatory milestone payments up to $200 million, sales milestone payments up to $5.725 billion, and sales royalties ranging from low single digits to low double digits. Hengrui Pharma will acquire a 19.9% equity stake in this new company as we continue to expand the global reach of our innovation and better serve unmet medical needs worldwide.